Defence Therapeutics Completes Fully Subscribed Debenture Units Financing of $2,000,000

Group 1 - Defence Therapeutics Inc. has successfully closed a non-brokered private placement of debenture units, raising a total of $2,000,000 [1][5] - Each debenture unit consists of one $1,000 principal amount 8.0% convertible debenture and 1,666 common share purchase warrants [1][2] - The debentures have a maturity date of September 15, 2027, and are convertible into common shares at a price of $0.60 per share [2][3] Group 2 - The company paid a total of $160,000 in cash finder's fees and issued 266,667 finder's warrants, which are also exercisable at $0.75 per share [4] - The net proceeds from the offering will be used to advance the company's science programs and for general working capital [5] - All securities issued are subject to a statutory hold period of four months plus a day from their date of issue [5] Group 3 - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) using its proprietary ACCUM® technology [7]